Sanmirna Therapeutics Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $4.25M

  • Investors
  • 1

Sanmirna Therapeutics General Information

Description

Developer of microRNA-based therapeutics designed to target leukemia stem cells and expand treatment options in oncology. The company offers a clinical-stage pipeline with Miristen™, advances preclinical programs in colorectal and lung cancer, applies precision mechanisms to exhaust treatment-resistant stem cells, integrates validated research from leading institutions, and maintains collaborations in oncology, enabling healthcare providers and pharmaceutical partners to access RNA-based therapies, reduce relapse rates, and pursue durable remission outcomes.

Contact Information

Website
www.sanmirna.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Paasheuvelweg 25-D5
  • 1105 BP Amsterdam
  • Netherlands
+31 020
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Thalia Therapeutics
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Paasheuvelweg 25-D5
  • 1105 BP Amsterdam
  • Netherlands
+31 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sanmirna Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 24-Jun-2026 $4.25M Completed Pre-Clinical Trials
1. Early Stage VC 24-Jun-2026 Completed Pre-Clinical Trials
To view Sanmirna Therapeutics’s complete valuation and funding history, request access »

Sanmirna Therapeutics Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Premier Miton Group Asset Manager Minority
To view Sanmirna Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Sanmirna Therapeutics FAQs

  • Where is Sanmirna Therapeutics headquartered?

    Sanmirna Therapeutics is headquartered in Amsterdam, Netherlands.

  • What industry is Sanmirna Therapeutics in?

    Sanmirna Therapeutics’s primary industry is Drug Discovery.

  • Is Sanmirna Therapeutics a private or public company?

    Sanmirna Therapeutics is a Private company.

  • What is the current valuation of Sanmirna Therapeutics?

    The current valuation of Sanmirna Therapeutics is .

  • What is Sanmirna Therapeutics’s current revenue?

    The current revenue for Sanmirna Therapeutics is .

  • How much funding has Sanmirna Therapeutics raised over time?

    Sanmirna Therapeutics has raised $3.18M.

  • Who are Sanmirna Therapeutics’s investors?

    Premier Miton Group has invested in Sanmirna Therapeutics.

  • When was Sanmirna Therapeutics acquired?

    Sanmirna Therapeutics was acquired on 24-Jun-2026.

  • Who acquired Sanmirna Therapeutics?

    Sanmirna Therapeutics was acquired by Thalia Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process